These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1967845)

  • 1. Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
    Gerlach J; Casey DE
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):103-12. PubMed ID: 1967845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropharmacological and behavioural properties of remoxipride in the rat.
    Ogren SO; Florvall L; Hall H; Magnusson O; Angeby-Möller K
    Acta Psychiatr Scand Suppl; 1990; 358():21-6. PubMed ID: 1978483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H; Gerlach J; Peacock L
    Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans.
    Kistrup K; Gerlach J
    Pharmacol Toxicol; 1987 Sep; 61(3):157-61. PubMed ID: 2891133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of haloperidol, remoxipride and raclopride on "pre"- and postsynaptic dopamine receptors in the rat brain.
    Magnusson O; Fowler CJ; Mohringe B; Wijkström A; Ogren SO
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Apr; 337(4):379-84. PubMed ID: 2900472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
    Ogren SO; Hall H; Köhler C; Magnusson O; Lindbom LO; Angeby K; Florvall L
    Eur J Pharmacol; 1984 Jul; 102(3-4):459-74. PubMed ID: 6149133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol.
    Lublin H; Gerlach J
    Eur J Pharmacol; 1988 Aug; 153(2-3):239-45. PubMed ID: 3263277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
    Peacock L; Gerlach J
    Eur J Pharmacol; 1993 Jun; 237(2-3):329-40. PubMed ID: 8103465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.
    Coffin VL; Latranyi MB; Chipkin RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):769-74. PubMed ID: 2567351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists.
    Pellissier G; Demenge P
    J Cardiovasc Pharmacol; 1991 Oct; 18(4):548-55. PubMed ID: 1724532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
    Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
    Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment.
    Peacock L; Lublin H; Gerlach J
    Eur J Pharmacol; 1990 Sep; 186(1):49-59. PubMed ID: 1980891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of the dopamine antagonist remoxipride on apomorphine induced behaviour in the rat.
    Ståhle L; Ljungberg T; Rodebjer A; Ogren SO; Ungerstedt U
    Pharmacol Toxicol; 1987 Mar; 60(3):227-32. PubMed ID: 2884654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.
    Wadworth AN; Heel RC
    Drugs; 1990 Dec; 40(6):863-79. PubMed ID: 1981869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
    Warawa EJ; Migler BM; Ohnmacht CJ; Needles AL; Gatos GC; McLaren FM; Nelson CL; Kirkland KM
    J Med Chem; 2001 Feb; 44(3):372-89. PubMed ID: 11462978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of remoxipride, a dopamine D-2 antagonist antipsychotic, on sleep-waking patterns and EEG activity in rats and rabbits.
    Ongini E; Bo P; Dionisotti S; Trampus M; Savoldi F
    Psychopharmacology (Berl); 1992; 107(2-3):236-42. PubMed ID: 1352054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration.
    Magnusson O; Mohringe B; Thorell G; Lake-Bakaar DM
    Pharmacol Toxicol; 1987 May; 60(5):368-73. PubMed ID: 2886989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
    Peacock L; Hansen L; Mørkeberg F; Gerlach J
    Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia.
    Andersson U; Häggström JE; Nilsson MI; Widerlöv E
    Psychopharmacology (Berl); 1988; 94(2):167-71. PubMed ID: 2895483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subchronic treatment of rats with remoxipride fails to modify sigma binding sites in the brain.
    Ericson H; Ross SB
    Eur J Pharmacol; 1992 Jun; 226(2):157-61. PubMed ID: 1353452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.